Abstract: Embodiments are disclosed for a method. The method includes generating a correction datastore indicating shifts in magnitude representing corresponding characters that uniquely identify hardware comprising a computer processing chip. The method further includes generating security masks based on a correction file. Additionally, the method includes using a correction process for the computer processing chip. The generated security masks include corresponding overlays representing the shifts in magnitude with respect to corresponding product masks for the computer processing chip. The method also includes generating the computer processing chip using the security masks and the product masks.

Abstract: An apparatus is provided for assisting in affixing a screen protector to a display of an electronic device. The apparatus includes a base including a platform configured to support the electronic device. The apparatus includes a lid configured to cover at least a portion of the base and the supported electronic device. The lid includes an aperture.

Abstract: The present disclosure provides methods and systems for secure logon. One or more method includes: determining, via authentication information provided by a user of an electronic device, that the user is authorized to access an online account provided by the online account provider; providing the user with a selectable option to enable an expedited logon process by which the user can access the online account by solely providing a particular authentication item of the user; receiving a verification credential in response to a next logon attempt using the expedited logon process; and verifying that the received verification credential matches an assigned verification credential provided to the user for use in conjunction with the next logon attempt using the expedited logon process.

Abstract: Disclosed is a hermetic AC electric motor that includes harmonics shunting such that high frequency harmonics are shunted from the AC electric motor without the use of one or more high frequency filters in the associated motor drive. A related method of operating an AC electric motor includes shunting high frequency harmonics to a fluid passing through the AC electric motor. Also disclosed is a simplified variable speed motor drive system which eliminates the need for a filter for removing high frequency harmonics.

Abstract: A modular omnidirectional hygienic conveyor belt constructed of a series of similar conveyor belt modules connected by pivot pins. Each conveyor belt module includes a modular laterally extending body having first spaced apart hinge eyes extending in a first direction and being connected to a first pivot pin and laterally offset second spaced apart hinge eyes extending in an opposed second direction and being connected to a second pivot pin. A plurality of spheres are captured by, engage and rotate omnidirectionally relative to upper and lower arcuate sphere contact surfaces of the body, which define for the spheres openly exposed opposed upper and lower spherical cap regions and openly exposed spherical segment regions therebetween, wherein openings in the body provide access for hygienic cleaning. A directional control system may drive the omnidirectional rotation of the spheres.

Abstract: The invention relates to the use of one or more fructokinase (ketohexokinase) (KHK) inhibitors to both prevent and treat a wide variety of diseases including, but not limited to, alcohol craving, alcohol addiction, alcohol induced liver disease including fatty liver and cirrhosis.

Abstract: Disclosed herein are methods and compositions for treating nonalcoholic fatty liver disease. Specifically exemplified herein is administration of compositions comprising a V1b inhibitor or V1a agonist or V1a stabilizer.

Abstract: The invention relates to the use of adenosine monophosphate deaminase 2 (AMPD2) inhibitors alone or in combination with various agents to treat a wide variety of diseases including, but not limited to, sugar craving, salt craving, umami craving, and addictions including drug, tobacco, nicotine and alcohol addictions. Embodiments of the invention may also relate to stimulation of AMPD2 activity to treat anorexia nervosa or stimulate food intake in a subject.

Abstract: The invention relates to the use of adenosine monophosphate deaminase 2 (AMPD2) inhibitors alone or in combination with various agents to treat a wide variety of diseases including, but not limited to, sugar craving, salt craving, umami craving, and addictions including drug, tobacco, nicotine and alcohol addictions. Embodiments of the invention may also relate to stimulation of AMPD2 activity to treat anorexia nervosa or stimulate food intake in a subject.

Abstract: Disclosed herein are methods and compositions for treating nonalcoholic fatty liver disease. Specifically exemplified herein is administration of compositions comprising a V1b inhibitor or V1a agonist or V1a stabilizer.

Abstract: The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease.

Abstract: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl.

Abstract: A composition for inhibiting ketohexokinase, for example, ketohexokinase-C (KHK-C) activity, may include a plant extract exhibiting at least IC50 (i.e., 50% KHK-C inhibition at a concentration in the range of from about 0.1 ?g/mL to about 1000 ?g/mL. The composition may be in a form suitable for oral ingestion. A method for inhibiting KHK-C activity in a subject may include administering a plant extract that exhibits at least 50% KHK-C inhibition at a concentration from about 0.1 ?g/mL to about 1000 ?g/mL. The administering may be done to treat or prevent at least one of sugar addiction, obesity, or metabolic syndrome. The administering may be done to provide a diminished craving in the subject from at least one member selected from the group consisting of craving of sugar, fructose, fructose-containing sugars, carbohydrates, and combinations thereof. The subject may be pre-diabetic, diabetic and or insulin resistant.

Abstract: A crew bunk system may include a bunk frame assembly and at least two vertically spaced crew berths. Each one of the crew berths may have a lengthwise hinge line dividing the crew berth into a stationary panel and a foldable panel. The stationary panel may be fixedly coupled to the bunk frame assembly. The foldable panel may be hingedly coupled to the stationary panel along the hinge line. The crew bunk system may include at least one connecting member interconnecting the foldable panels such that the foldable panels pivot in unison between a deployed position and a stowed position. The crew bunk system may include a latching mechanism configured to lock the foldable panels in the stowed position.

Abstract: A system for restricting mixing of air in a data center includes a plurality of racks, each of the racks having a front face and a back face. The system includes an enclosure for collecting air released from the back faces of the plurality of racks, the enclosure configured to substantially contain the air in an area between the first row and the second row and having a roof panel coupled to the first row of racks and the second row of racks configured to span a distance between the first row of racks and the second row of racks. The enclosure is configured to maintain a first air pressure inside of the enclosure that is substantially equal to a second air pressure outside the enclosure.

Abstract: The present invention provides compounds and compositions that modulate adenosine monophosphate deaminase (AMPD) and methods for using the same to treat a clinical condition associated with the metabolic syndrome or a disease associated with the metabolic syndrome. In particular, the present invention provides a compound and a composition comprising a selective AMPD2 inhibitor and methods for using the same, for example, to treat a clinical condition associated with metabolic syndrome as well as diseases manifested by the metabolic syndrome.

Abstract: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.2 to 5.5 mg/dl.

Abstract: The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease.

Abstract: The present invention provides compounds and compositions that modulate adenosine monophosphate deaminase (AMPD) and methods for using the same to treat a clinical condition associated with the metabolic syndrome or a disease associated with the metabolic syndrome. In particular, the present invention provides a compound and a composition comprising a selective AMPD2 inhibitor and methods for using the same, for example, to treat a clinical condition associated with metabolic syndrome as well as diseases manifested by the metabolic syndrome.

Abstract: A system for restricting mixing of air in a data center includes a plurality of racks, each of the racks having a front face and a back face. The system includes an enclosure for collecting air released from the back faces of the plurality of racks, the enclosure configured to substantially contain the air in an area between the first row and the second row and having a roof panel coupled to the first row of racks and the second row of racks configured to span a distance between the first row of racks and the second row of racks. The enclosure is configured to maintain a first air pressure inside of the enclosure that is substantially equal to a second air pressure outside the enclosure.